SOMATROPIN
Manner of administration:Injection
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Recommencement of treatment
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Recommencement of treatment
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Recommencement of treatment
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Recommencement of treatment as a reclassified patient
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $197.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Saizen | |||||
Manner of administration:Injection
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Continuing treatment
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Continuing treatment
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Continuing treatment
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Continuing treatment
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Continuing treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Change of drug
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Change of drug
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $197.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Saizen | |||||
Manner of administration:Injection
Restriction
Indication: Severe growth hormone deficiency
Treatment phase: Initial treatment of late onset growth hormone deficiency
Restriction
Indication: Severe growth hormone deficiency
Treatment phase: Continuing treatment in a person with a mature skeleton or aged 18 years or older
Restriction
Indication: Severe growth hormone deficiency
Treatment phase: Initial treatment of childhood onset growth hormone deficiency in a patient who has
received PBS-subsidised treatment as a child
Restriction
Indication: Severe growth hormone deficiency
Treatment phase: Initial treatment of childhood onset growth hormone deficiency in a patient who has
received non-PBS subsidised treatment as a child
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $197.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Saizen | |||||
Manner of administration:Injection
Restriction
Indication: Short stature and slow growth
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Initial treatment
Restriction
Indication: Growth retardation secondary to an intracranial lesion, or cranial irradiation
Treatment phase: Initial treatment
Restriction
Indication: Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants
Treatment phase: Initial treatment
Restriction
Indication: Biochemical growth hormone deficiency and precocious puberty
Treatment phase: Initial treatment
Restriction
Indication: Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic
obesity driven growth
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with Turner syndrome
Treatment phase: Initial treatment
Restriction
Indication: Short stature due to short stature homeobox (SHOX) gene disorders
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with chronic renal insufficiency
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $197.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Saizen | |||||